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Abstract 
Background: Interferons play an important role in innate immunity. Previous studies report 
deficiency in virus-induction of interferon (IFN)-α, -β and -λ in bronchial epithelial and bronchial 
lavage cells in atopic asthmatics. It is now recognized that asthma is a heterogeneous disease 
comprising different inflammatory phenotypes, some of which may involve innate immune 
activation in the absence of overt infection. 
Objective: The aim of the study was investigate if the severity of asthma or a specific cellular sputum 
pattern may be linked to evidence of innate immune activation. 
Methods: Here we investigate the expression of IFN-β, IFN-λ1 (IL-29), IFN-λ2/3 (IL-28A/B) and the 
interferon-stimulated genes (ISGs) myxovirus resistance 1 (Mx1), oligoadenylate synthetase (OAS) 
and viperin in unstimulated sputum cells in 57 asthmatics (including 16 mild, 19 moderate and 22 
severe asthma patients) and compared them with 19 healthy subjects. 
Results: We observed increased expression of IFN-β, IFN-λ1/IL-29, OAS and viperin in asthmatic 
compared to healthy subjects while IL-28 was not expressed in any group. The overexpression was 
restricted to neutrophilic asthmatics (sputum neutrophils ≥ 76%) while eosinophilic asthmatics 
(sputum eosinophils ≥ 3%) did not differ from healthy subjects or even showed a lower expression of 
Mx1. No difference in interferon or ISG expression was seen according to clinical asthma severity. 
Conclusion and clinical relevance: Neutrophilic, but not eosinophilic, asthmatics display 
overexpression of IFN−β, IFN–λ1/IL-29 and ISGs in their sputum cells that may reflect ongoing innate 
immune activation. 
 
Key words: asthma phenotype, neutrophils, eosinophils, interferon β and λ, interferon stimulated 
genes 
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Introduction 
Interferons beta (IFN-β) and lambda (IFN-λ) play a crucial role in host defense against infectious 
agents. There is evidence that asthmatics may show impaired innate immunity resulting in inefficient 
clearing of viruses from epithelial cells [1]. This was shown to be related to a reduced production of 
IFN-β and IFN-λ from bronchial epithelial cells [2,3] and IFNs -α,  -β and −λ from bronchoalveolar 
lavage cells upon cell infection [2,4]. A recent study has suggested that these deficiencies may be 
related to asthma severity in children [5] while they were not found in well controlled adult 
asthmatics [6]. A genome wide transcriptional analysis on primary bronchial epithelial cells from 
normal and atopic asthmatic donors showed similar response to rhinovirus infection including IFN-β 
and IFN-λ upregulation [7]. 
The technique of induced sputum has proved to be useful to investigate the cytokine network in 
airway cells of asthmatics [8] Measurement of proteins by ELISA in the cell culture supernatant 
[9,10], sputum supernatant as well as measurement of the gene expression in sputum cells have 
been used to characterize airway cytokine networks in asthma. A previous study has specifically 
investigated the expression of IFN-λ in sputum cells from children and adult asthmatics and found a 
higher expression of IL-28 in asthmatics, particularly in children, which correlated with eosinophil 
counts while expression of IL-29, which also tended to be higher, was inversely correlated with the 
symptoms [11].   In another study IFN-λ mRNA was measured in sputum cells and found to be lower 
at resolution of exacerbation in asthmatics who had the more severe symptoms during viral positive 
cold [12]. 
It is now recognized that asthma is a heterogeneous disease featuring several clinical and 
inflammatory phenotypes [13] with different underlying molecular mechanisms [14]. While asthma 
is often associated with airway and/or systemic eosinophilic inflammation that makes patients prone 
to exacerbate [15], a significant proportion of asthmatics display persistent non eosinophilic 
phenotype [16]. One phenotype suggested by previous workers includes evidence of innate immune 
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activation in neutrophilic asthma, perhaps as a consequence of airway colonization with microbes in 
the absence of evidence of overt airway infection [17].  
The purpose of this study is to determine whether the severity of asthma or a specific cellular 
sputum pattern may be linked to evidence of innate immune activation. Here we have examined 
sputum samples from asthmatics of various severities and sputum cell compositions for the 
expression of interferons (IFN-β, IFNs-) and interferon stimulated genes (ISGs), such as myxovirus 
resistance 1 (Mx1) [18], oligoadenylate synthase (OAS) [19] and viperin [20]. Though none of the 
patients included in our study was in exacerbation, we also investigated the presence of 
picornaviruses in sputum samples. Our results show that expression of interferons and ISGs in 
sputum cells is more influenced by the type of airway inflammatory pattern than the clinical disease 
severity. 
 
Methods 
1- Subject characteristics and study design 
The study was performed in subjects recruited from the University Asthma Clinic of Liege between 
June 2011 and September 2013. Asthma was diagnosed on the basis of chronic respiratory 
symptoms such as cough, breathlessness or dyspnea associated with airway hyper-responsiveness, 
demonstrated by one or more of the following criteria: increase in forced expiratory volume in one 
second (FEV1) of >12% and 200 mL following inhalation of 400μg salbutamol or inhaled 
concentration of methacholine provoking a 20% fall in FEV1 of <16 mg/mL. Clinical assessment at the 
Asthma Clinic was previously reported [21] and included the evaluation of asthma control by the 
Juniper Asthma Control Questionnaire (ACQ). None of the recruited asthmatics selected for this 
study was in an exacerbation state requiring initiation or increasing the current dosage of systemic 
corticosteroids within 4 weeks of sputum samplings. None of them had overt sign of acute 
pneumonia the day of sputum induction. Atopy was determined by positive skin-prick test to at least 
one common aeroallergen (cat, dog, house dust mite, grass pollen, tree pollen and a mixture of 
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moulds). Mild asthmatics were patients with intermittent symptoms, normal baseline lung function 
(FEV1 > 80% predicted) and not treated by inhaled corticoids (ICS) while moderate asthmatics were 
receiving maintenance treatment with moderate doses ICS combined to long acting β2 agonists 
(LABA) or leukotriene receptor antagonist (LTRA). Refractory asthma was defined according ATS 
criteria [22], after an extensive evaluation of the patients. These patients had profound lung function 
impairment despite receiving high dose ICS mostly combined with LABA. Based on sputum cellularity 
characteristics, patients were classified as eosinophilic phenotype, defined as ≥3% sputum 
eosinophil count, neutrophilic phenotype, consisted of ≥76% sputum neutrophil counts, mixed 
granulocytic phenotype, when both neutrophil and eosinophil counts were increased or pauci-
granulocytic phenotype, when both cell types were under the percentages described above. The cut-
off of 76% for neutrophil counts was chosen from the 90% confidence interval of a sputum 
neutrophil count observed in a series of 113 healthy subjects recruited in our hospital by 
advertisement. The mean was 35% and standard deviation was 24%; thus the upper limit of the 90% 
CI only let 5% of normal subjects above this threshold and can be derived by the formula mean+1.7 
SD [23]. 
Healthy controls were recruited by local advertisement in the hospital. None of them exhibited 
respiratory symptoms or had airways hyperresponsiveness (provocative concentration of 
methacholine causing a fall in FEV1 of 20% > 16 mg/mL) and all had normal lung function (FEV1 >80% 
predicted value).  
The study was approved by our local Ethics Committee and subjects signed informed consent. 
 
2. Sputum induction and processing 
Sputum was induced and processed as previously reported [23]. Cell viability was checked by trypan 
blue exclusion and after counting 500 non squamous cells, the differential count was performed on 
cytospins stained with RAPI DIFF II® stain kit (Atom Scientific, Manchester,UK). When a poor quality 
sample was detected (squamous cell fraction greater than 30%), the sputum was excluded from the 
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analyses. Collected cells were centrifuged and the pellet (1 to 2.106 cells) was mixed with 400µL of 
RNAprotect® cell reagent (Qiagen, Hilden, Germany) and kept at -80°C until RNA extraction. 
During the recruitment for this study 8 subjects were excluded because of poor quality of sputum 
sample (2 healthy subjects, 2 intermittent asthmatics, 2 moderate and 2 severe asthmatics). Then, 
sputum induction was performed in 84 subjects of whom 76 were suitable for gene expression 
analysis. 
 
3. RNA extraction/isolation and cDNA synthesis 
After removing RNAprotect cell reagent, the pellet was resuspended in 500µL of TriPure isolation 
Reagent (Roche Applied Science), to which was added one bead (Stainless Steel Beads, 5mm, 
Qiagen). The sample was disrupted and homogenized using a TissueLyser system (TissueLyser II, 
Qiagen), for 2 min at 25 Hz. The RNA was separated by phenol-chloroform extraction. The upper 
aqueous phase (300 µL) was diluted with equal volume of ethanol and transferred to a NucleoSpin 
RNA binding column (Macherey-Nagel). Washing and drying of silica membrane and RNA elution 
were executed according to NucleoSpin RNA clean-up protocol (Macherey-Nagel). The residual 
genomic DNA was eliminated by a treatment DNAse with TURBO DNA-free™ kit of Ambion (Thermo 
Fisher Scientific, Wilmington, USA). The RNA concentration and purity were assessed by Nanodrop 
ND-1000 spectrophotometer. The cDNA was prepared from maximum 1µg of RNA using QuantiTect® 
Reverse Transcription kit of Qiagen.  
 
4. TaqMan Real Time Polymerase Chain reaction (qPCR) 
Quantitative PCR was performed with a 384 well plate (MicroAmp®Optical) on a 7900HT system 
(Applied Biosystems) using the QuantiTect® Probe PCR kit (Qiagen). The real-time reaction mixture 
was prepared in a total volume of 10µL PCR reaction and 1 µL cDNA. The cycle parameters were as 
follows: initial enzyme activation at 95°C for 15 min, followed by 40 cycles of sequential incubations 
at 94°C for 15 s and at 60°C for 1 min and one cycle at 40°C for 30 seconds. 
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Primer pairs and probes, all FAM-TAMRA labelled, were selected according to description of Gielen 
et al [24] for 18s, OAS, IFN-β, Mx1, viperin, and IL-28. For IL-29, probe: 
AGTTGCAGCTCTCCTGTCTTCCCCG, forward: CCTTGGAAGAGTCACTCAAGCT and reverse: 
AGAAGCCTCAGGTCCCAATT, (accession number: NM_172140.1), which were purchased from 
Eurogentec (Seraing, Belgium). For each sample a supplementary PCR from RNA for IL-28, IL-29 and 
IFN-β was performed to verify the absence of residual genomic DNA. Copy numbers of each gene 
were determined via standard curves constructed as dsDNA plasmids, and normalized with the 
housekeeping gene 18S rRNA. We chose a cut-off of 20 CT for the 18S and excluded samples in 
which more than 20 CT was needed to pick up 18S (8 out of 84 samples initially tested). The mean CT 
for 18S was 14.1±1.8 CT in our series of experiments. 
 
5. Measurement of IFN-β and IL-29 proteins in sputum supernatant 
A pool of sputum supernatants from healthy subjects and asthmatic patients was spiked with IL-29 
(range from 60 to 1000pg/mL) or IFN-β (range from 50 to 2000pg/mL) to construct standard curves. 
Sputum samples were diluted 1/10 for IL-29 and 1/2 for IFN-β measurements and compared to the 
standard curves to quantify IFN proteins using commercial kits to IL-29 (Human IL-29/IFN-lambda 1 
DuoSet ELISA Kit, R&D Systems) and IFN-β (VeriKine Human IFN Beta ELISA Kit, Pestka Biomedical 
Laboratories). The recovery in the lower concentrations were 24% for IL-29 and 26% for IFN-β. 
 
6. Detection of virus RNA 
Four µl of cDNA was then used to detect picornaviruses in a single round PCR of 32 cycles [25]. 
Differentiation of rhinoviruses from other picornaviruses was achieved by restriction enzyme 
digestion of the PCR product [26]. 
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7. Statistical analysis 
Data were analyzed using a statistical software package (GraphPad Prism, Version 5). Results were 
expressed as median (range) for non-parametric data, and as mean (± standard deviation) for 
parametric data. Frequency was used to summarize categorical data. Groups were compared for 
qualitative data by Fisher’s exact t. For quantitative data groups were compared by the Kruskal-
Wallis test and post-hoc Dunn’s test. Parametric data were analyzed by ANOVA with post-hoc two 
sample t-testing with Bonferroni correction. Spearman's Rank correlation coefficient was used to 
identify relationships between variables that show non-parametric distribution; p-values ≤0.05 were 
considered statistically significant. 
 
Results 
Patient characteristics 
The patient characteristics according to asthma severity are given in table 1. Refractory asthmatics 
were patients observed for period of at least 6 months and were characterized by markedly reduced 
flow rates and FEV1/FVC ratio accompanied by uncontrolled symptoms reflected by higher ACQ 
score despite high dose of inhaled corticoids mostly combined with long acting β2-agonists. The 
sputum cytology of the four groups is shown in table 2. 
 
Detection of IFNs and ISGs in asthma 
Overall IFN-β expression was detected in 23 of 57 asthmatics and in only 1 of 19 healthy subjects 
(p<0.01). IL-29 was detected in 31 of 57 asthmatics and 2 of 19 healthy subjects (p<0.001). Viperin 
expression was increased in asthmatics (p<0.01) while that of Mx1 was slightly decreased (p=0.05). 
No difference was seen with respect to OAS (Figure 1). Sputum supernatants from healthy subjects 
(15 out of 19 samples) and asthmatics (47 out of 57 samples) were analyzed for IL-29 and IFN-β 
proteins. IL-29 protein was detectable in only one healthy subject (76pg/ml) and 4 asthmatics (range 
from 74 to 113 pg/ml). Among them 3 samples from asthmatics were also positive for IL-29 mRNA. 
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As for IFN-β protein, 3 healthy subjects (range from 115 to 187 pg/ml) and 6 asthmatics (range from 
115 to 201 pg/ml) had positive samples. Among them 4 samples from asthmatics had IFN-β gene 
expression detected in sputum cells. 
Relationship between IFNs and ISGs and smoking and ICS 
Overall IFN-β expression weakly correlated with pack-years (r=0.25, p<0.05). No significant 
relationship with smoking history was found for IL-29 and the ISGs (p>0.05 for all) even if there was a 
trend for IL-29 and viperin (r=0.20; p=0.08). There was no difference between asthmatics treated 
(N=40) and not treated with ICS (N=17) with respect to IFNs and ISGs but only ICS treated (N=40) 
asthmatics had raised IL-29 (p<0.01), IFN-β (p<0.05) and viperin (p<0.05) compared to healthy 
subject. 
 
Relationship between IFNs and ISGs and asthma severity 
There was no difference in IFN-β and IL-29 expression or in interferon-stimulated genes (ISGs) 
according to disease severity (Table 3). In addition there was no correlation between asthma control 
(ACQ) and FEV1 and any of the interferons and ISGs (Table 4). 
 
Relationship between IFNs and ISGs and sputum cellularity in asthmatics 
There were too few asthmatics with mixed granulocytic cellularity (n=5) to make pertinent statistical 
analyses, thus analyses are restricted to the other three groups. When classified according to their 
sputum granulocyte cell counts (Table 5), neutrophilic asthmatics were clearly characterized by an 
increased expression on IFN-β and IL-29 together with interferon-stimulated gene viperin compared 
to eosinophilic asthmatics and healthy subjects (Figure 2). Neutrophilic asthmatics had also greater 
IFN-β and IL-29 expression compared to pauci-granulocytic asthmatics. Pauci-granulocytic 
asthmatics had greater expression of Mx1 compared to eosinophilic asthmatics in whom Mx1 gene 
expression was even lower than in healthy subjects (Figure 2). 
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Relationship between IFNs and smoking, ICS and neutrophils. 
In a multivariate analysis including smoking status, ICS dosage and sputum neutrophils we found 
that sputum neutrophils was the dominant factor associated with raised IL-29 and IFN-β in 
asthmatics (Table 6).   
 
Relationship between IFNs and ISGs and between sputum cellularity and IFNs and ISGs 
For the whole asthmatic group there was a strong correlation between gene expression of IFN-β and 
IL-29 (r=0.75, p<0.001) and, to a lesser extent, between IFNs and ISGs (Table 7). The relationship 
between sputum cell counts and interferon and/or interferon induced genes are given in table 8. 
IFN-β, IL-29 and viperin correlated with sputum neutrophils while OAS and Mx1 inversely correlated 
with sputum eosinophils. 
 
Detection of picornavirus in sputum samples 
Only 4 subjects out of 68 tested had detectable picornavirus in their sputum sample including 3 
healthy subjects (all picornaviruses) and 1 moderate asthmatic in which human rhinovirus was 
identified. Their sputum neutrophil counts were 87, 88, 60 and 57% respectively. IL-29 was 
detectable in two of the 4 subjects (1 healthy with picornavirus [256 copies/μL] and 1 asthmatic with 
rhinovirus [24 copies/μL]) but IFN-β was undetectable in all four. In these 4 subjects ISGs were 
unremarkable compared to the subjects negative for viruses (data not shown) 
 
Discussion 
Our study shows that asthmatics express greater amount of interferon and interferon stimulated 
genes in unstimulated sputum cells compared to healthy subjects. However, this overexpression is 
essentially accounted for by the group of neutrophilic asthma while this expression seems to be 
normal and, even to some extent, reduced in eosinophilic asthma. 
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Although sputum sampling is a convenient technique to sample the airways the interferon-β and -λ 
pathways have been poorly investigated so far. One previous study investigating both children and 
adult stable asthmatics showed increased expression in IL-28 and IL-29 in unstimulated sputum cells 
from asthmatics and particularly in children [11]. Another recent study has shown a trend for raised 
expression of IFN-β in sputum cells in adult asthmatics during a viral asthma exacerbation while IFN-
λ1 did not change [27]. Our data confirm the increased IL-29 expression in stable asthma and 
extends this finding by showing increased IFN-β and a corresponding increase in the interferon 
stimulated gene viperin. Our study has included adult asthmatics encompassing the all disease 
severity spectra allowing for meaningful evaluation of a link between interferon expression and 
disease severity. In our study, no convincing relationship was found between disease severity and 
interferon gene expression. Furthermore gene expression was unrelated to FEV1 or asthma control. 
We know that severe asthma is a heterogeneous disease with respect to airway inflammation with 
half of patients displaying residual eosinophilic inflammation while the other half shows either pure 
neutrophilic or no clear airway inflammation [28].  
Here we bring up new relevant information by showing that the interferon pathway is essentially 
upregulated in a specific sub-group of asthmatics with elevated sputum neutrophil counts. Our 
finding is in line with the rise of sputum IFN-β RNA associated with a neutrophil recruitment in the 
airways during an acute viral exacerbation [27]. Interestingly Simpson et al have recently 
demonstrated that PBMC from neutrophilic asthmatics released less IFN-α and IFN-β in response to 
a stimulation with rhinovirus in vitro [29]. This apparent discrepancy may be explained by the 
different compartments (blood vs airway) that were investigated. Our findings are in airway cells 
where bacteria/virus presence in the airway might explain high sputum neutrophil counts and basal 
interferon levels, the same might not be true for the PBMCs that Simpson et al studied as they 
would not be exposed to the bacteria/virus. Among the ISGs, viperin was the one whose expression 
best correlated with IFNs -β and -λ, and was the one most markedly increased in neutrophilic 
asthma.  
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The results in our study reflect the overall gene expression from a mixture of sputum cells. Therefore 
we can only speculate about the main cell source of gene expression. However the fact that 
interferons and ISG are increased in neutrophilic asthma suggests that neutrophils may be a 
potential source of interferons and ISG gene expression. Alternatively we cannot rule out the fact 
that increased expression of IFNs and ISGs may favour neutrophilic airway infiltration. The increased 
cytokine expression in neutrophilic asthma supports the concept of innate immune activation in this 
phenotype [17]. Whether neutrophilic inflammation and interferon gene expression reflect an 
infectious process within the airways remains to be demonstrated. Though we did not systematically 
assess airway microbial status in this study none of the recruited patients had an overt acute lower 
respiratory tract infection at the time of sputum sampling. Wood et al found only 15% of stable 
asthmatics to be colonized with potentially pathogen microorganism (PPM) [30]. We also know from 
personal observation that only a minority of neutrophilic asthmatics show airway bacterial 
colonization by positive sputum culture. Indeed retrospective analysis from our asthma clinic data 
base identified 36 patients with sputum neutrophil counts > 76% in whom the clinician had 
specifically asked for a microbiology analysis for suspicion of infection. Only 14 out of them had PPM 
at sputum culture. Nevertheless it does not exclude a lower microbial burden that might have been 
identified through more sensitive technique like gene analysis [31]. Indeed people with asthma 
(without knowledge of their airway inflammatory cell status) have been recently reported to have an 
increased burden of potentially pathogenic organisms in their lower airway when stable [32]. In 
addition, a recent study that used 16S rRNA pyrosequencing for microbial community profiling has 
shown reduced bacterial diversity and a high prevalence of Haemophilus influenzae in neutrophilic 
asthma [33]. With the advent of sputum cell PCR analysis our current study discards infection with 
picornavirus, and in particular with rhinovirus, in all but 4 subjects. Among them, rhinovirus was 
detected in only 1 non-neutrophilic moderate asthmatic. On the other hand it has been established 
that neutrophils can be recruited by non-specific stimuli such as saline [34], cold air [35] or as a 
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result of airway irritation by air pollutants [36-38]. Our study cannot clarify whether the interferon 
pathway is activated here as a consequence of airway infection/colonisation or just airway irritation. 
 
In sharp contrast with what was shown in neutrophilic asthmatics, eosinophilic asthmatics did not 
show any increase in IFNs or ISGs when compared to healthy subjects and even displayed a reduced 
expression of Mx1. The striking difference between neutrophilic and eosinophilic asthma with 
respect to interferon pathway activation is in keeping with previous studies pointing to different 
molecular mechanisms in neutrophil vs eosinophilic asthma, where cellular pattern rather than 
clinical severity shows association with molecular pathways [39-42]. 
 
Mx1 was different from other ISGs with respect to its expression being possibly reduced when 
comparing all asthmatics to healthy control subjects, with a P value of borderline significance at 
P=0.05, while OAS expression was not significantly different between groups, and IL-29, IFN-β and 
viperin were all increased in asthma.  The reduced Mx1 expression in eosinophilic asthma suggests 
that this asthma phenotype might be more susceptible to viral airway infection, Mx1 represents a 
first line of defense against viral infection inside the cell and its increased expression may be seen as 
a sign of ongoing innate immune activation [43], of increased constitutive expression or it could be a 
spurious finding. We believe these findings should be interpreted with caution due to the relatively 
low numbers of healthy subjects included, and of asthmatics subjects once divided into sub-groups. 
A recent study has shown that treatment with inhaled interferon-β may help severe asthmatics to 
speed up clinical recovery during an exacerbation due to a common cold [44]. However no patient 
selection according to airway inflammatory pattern was performed before entering the patients in 
the protocol and it would be of great interest to see whether the size effect could even be stronger 
in selected eosinophilic asthmatics.  
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One limitation of our study is the cross sectional design precluding any conclusion on the stability of 
the inflammatory phenotype over time. Therefore we cannot state that some asthmatics 
permanently express high or low IFNs and ISGs in their airways. In contrast we believe it is likely to 
fluctuate according to the airways exposure to offending microbes or particles.  
 
How do our findings relate to many other publications showing that cells from asthmatic airways 
have reduced type I and type III IFN production in response to rhinovirus infection ex vivo [2-5]? We 
believe the most likely explanation is that our finding of increased IFN and ISG expression in mixed 
sputum cells with no ex vivo infection or stimulation reflects ongoing innate immune stimulation of 
sputum cells in people with neutrophilic asthma, most likely a consequence of increased bacterial 
burden in the airways of these subjects. Our processing methods (use of DNAse) did not allow 
investigation of bacterial burden by analysis of bacterial DNA with molecular techniques in these 
samples, so we were unable to determine if that hypothesis is true in the present study. Our findings 
are consistent with the literature reporting deficient/delayed IFN induction in asthma, as current 
mechanistic explanations for this phenomenon, are that it is at least in part a consequence of 
increased airway inflammation (in the present study neutrophilic) inducing SOCS1[45], Th2 cytokines 
[46] and/or TGF-β [47-49], thereby actively suppressing IFN induction in response to virus infection. 
In conclusion neutrophilic, but not eosinophilic, asthmatics show increased sputum interferon-β and 
-λ gene expression together with increased ISG(s). Whether this reflects innate immune activation 
against colonizing microbes or altered microbiome remains to be demonstrated in a further study. 
The reduced Mx1 expression in eosinophilic asthmatics, if confirmed in future studies, may make 
them more prone to viral infections. 
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Table 1: Patient characteristics according to asthma severity 
 Healthy subjects 
Mild   
asthmatics 
Moderate asthmatics 
Refractory 
asthmatics 
 (N = 19) (N = 16) (N = 19) (N = 22) 
Age (years) 48 ± 15 53 ± 16 51 ± 17 53 ± 9 
Sex (m/f) 10/9 4/12 7/12 6/16 
Tobacco status 
(ns/es/cs) 
9/7/3 6/10/0 12/5/2 5/10/7 
Pack-year 
0.2 
(0-42) 
17 ººº $$ 
(0-27) 
0 * && º
(0-30) 
24.8 *** 
(0-90) 
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Atopy 
7  
(37%) 
11  
(69%) 
15  
(79%) 
12  
(57%) 
FeNO (ppb) 
24.3  
(4.1-48.7) 
34.3 º 
(10.2-101) 
33.5 º 
(10-116) 
15.7  
(4.3-42.5) 
IgE Nd 
106  
(19-611) 
213  
(11-4379) 
232  
(12-1787) 
FEV1 (% Pred) 100 ± 13.7  94.5 ± 12.19 ººº 91.37 ± 12.75 ººº 50.59 ± 14.41*** 
FVC (% Pred) 106.72 ± 12.5  105.69 ± 10.52 ºº 103.53 ± 14.89 ºº 79.48 ± 22.09*** 
FEV1/FVC (%) 77.64 ± 5.49  74.84 ± 7.58 ººº 73.76 ± 6.51 ººº 53.49 ± 8.79*** 
Reversibility (%) Nd 9.46 ± 5.5 6.5 ± 7.29 11.68 ± 15.07 
ACQ Nd 0.97 ± 0.56 ººº 1.42 ± 0.99 ººº 3.56 ± 1.24 
PC20M (mg/ml) >16 
1.2  
(0.1-15.4) 
1.9  
(0.2-22) 
0.27 and 6.09 N 
 
Oral CS (0%) 0 (0%) 0 (0%) 5 (23%) 
Inhaled CS (0%) 0 (0%) 18 (95%) 22 (100%) 
Inhaled CS 
(eq becl/day) 
0 0 ººº $$$ 
1000 ***  
(0-2000) 
2000 *** 
(800-4400) 
LABA - 0 (0%) 16 (84%) 22 (100%) 
LTRA - 1 (6%) 8 (42%) 16 (73%) 
Theophylline (0%) 0 (0%) 0 (0%) 4 (18%) 
 
Results are presented as absolute number, absolute number (percentage), mean ± SD or median 
(range); n: non-smoker; ex: ex-smoker; cs: current smoker; FENO: exhaled nitric oxide; FEV1: forced 
expiratory volume in 1"; FVC: forced vital capacity; PC20M: metacholine concentration required to 
provoke a fall of 20% or more in FEV1; ACQ: Asthma Control Questionnaire; LABA: long-acting beta-
agonist bronchodilators; LTRA: leukotriene receptor antagonists, nd: not done * p<0.05, ** p<0.01, 
*** p<0.001 versus healthy subjects; $ p<0.05, $$ p<0.01 versus moderate asthmatics; & p<0.05, && 
p<0.01 versus mild asthmatics; ° p<0.05, ºº p<0.01, ººº p<0.001 versus refractory asthmatics. N Note: 
only for two refractory asthmatics. 
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Table 2: Sputum cytology according to asthma severity 
 Healthy subjects Mild Asthmatics 
Moderate 
asthmatics 
Refractory 
asthmatics 
Sputum weight (g) 4  
(1.4-10.3) 
3.7  
(0.4-11.8) 
3.8  
(0.9-11.0) 
2.2  
(0.3-16.6) 
Total non-squamous 
cells (106/g) 
1.1  
(0.1-11.6) 
1.7  
(0.3-29.0) 
1.8  
(0.2-17.5) 
2.7 * 
(0.5-37.7)  
Squamous cells (%) 13.2  
(0-30) 
6  
(1-30) 
14  
(0-24) 
5  
(0-30) 
Viability (%) 77  
(42.8-92.0) 
77.5  
(45-96) 
78  
(50-95) 
74.5  
(40-97) 
Macrophages (%) 37  
(6-88) 
19.7  
(1.6-90.5) 
27.3  
(1.0-67.4) 
9 *** 
(1.5-98.0)  
Macrophages (10³/g) 418.1  
(36.6-2772.0) 
392  
(23.4-6812.7) 
387.4  
(31.7-1817.9) 
395.3  
(14.6-4106.2) 
Lymphocytes (%) 2.2  
(0-7) 
0.9  
(0.0-5.8) 
1.4  
(0.0-6.6) 
1.5  
(0-7) 
Lymphocytes (10³/g) 21.9  
(0.0-417.2) 
29.4  
(0.0-472.1) 
14.8  
(0.0-207.9) 
18.7  
(0.0-589.5) 
Neutrophils (%) 55.3  
(4-88) 
49.2  
(3-98) 
53  
(15.4-98.0) 
72.3  
(0-98) 
Neutrophils (10³/g) 442.4 
(60.4-10036.9) 
820.7  
(103.8-12730.3) 
701.7  
(56.8-15627.1) 
1568.3 * 
(0-27734)  
Eosinophils (%) 0  
(0.0-11.4) 
4.9 *** 
(0.0-70.7) 
2 * 
(0-22) 
4 *** 
(0-92)  
Eosinophils (10³/g) 0  
(0-371) 
119 *** 
(0-15365) 
36  
(0-436) 
137 *** 
(0-34684)  
Epithelial cells (%) 2  
(0-15) 
2  
(0-10) 
6  
(0-33) 
4  
(0-29) 
Epithelial cells (10³/g) 23  
(0-180) 
25  
(0-2247) 
54  
(0-726) 
127* 
(0-5175)  
Results are presented as median (range); * p<0.05, *** p<0.001 versus healthy subjects. 
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Table 3: Gene expression of interferons and interferon-induced genes in sputum cells according to 
asthma severity 
 Healthy subjects Mild Asthmatics 
Moderate 
asthmatics 
Refractory 
asthmatics 
IL-28      
(copy/µL) 
0 
(0-33) 
0  
(0-0) 
0  
(0-0) 
0  
(0-0) 
IL-29      
(copy/µL) 
0  
(0-256) 
2 * 
(0-2920) 
4 ** 
(0-1305) 
73 ** 
(0-9712) 
IFN-β 
(copy/µL) 
0  
(0-2) 
0 * 
(0-7281) 
0 * 
(0-1609) 
0 ** 
(0-5366) 
Mx1       
(copy/µL) 
3855  
(744-62906) 
2542,4  
(93-55944) 
2729  
(0-29300) 
2575 * 
(161-22792)  
OAS        
(copy/µL) 
771  
(0-4953) 
1084  
(35-9205) 
724  
(191-3138) 
1080  
(0-16218) 
Viperin    
(copy/µL) 
349  
(0-1123) 
1205 ** 
(0-20534) 
477  
(107-16377) 
1739 * 
(0-72222)  
Results are presented as median (range); * p<0.05, ** p<0.01 versus healthy subjects.
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Table 4: Matrix of correlation between IFNs and ISGs expression and indices of asthma control 
  ACQ   FEV1 % pred
  p value r p value r 
     
IL29 0.76 0.04 0.78 0.04
IFNβ 0.68 -0.06 0.21 0.17
Mx1 0.33 -0.14 0.20 0.17
OAS 0.80 0.03 0.68 -0.05
Viperin 0.48 0.10 0.77 -0.04
ACQ: asthma control test. r: Spearman coefficient. 
 
Table 5: Demographic, functional and inflammatory characteristics according to sputum cellular 
phenotypes 
 Healthy 
subjects 
Pauci-granulocytic 
asthma 
Eosinophilic 
asthma 
Neutrophilic 
asthma 
 (N = 19) (N = 11) (N = 27) (N = 14) 
Age (yrs) 48 ± 15 45 ± 17 54 ± 9 54 ± 13 
Sex (m/f) 10/9 5/6 9/18 2/12 
Tobacco status 
(ns/es/cs) 
9/7/3 5/5/1 13/11/3 2/7/5 
Pack-year 7 (0-25) 7 (0-30) 0,5 (0-60) 17 (0-40) 
Atopy (%) 7 (37%) 6 (55%) 19 (73%) 8 (57%) 
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NO (ppb) 24 (4-48) 13 (4-70) 35 (6-116) 20 (6-68) 
IgE (KU/l) Nd 60 (11-537) 206 (27-611) 287 (12-4379) 
FEV1 (% pred) 100 ± 14 83 ± 23 76 ± 21** 68 ± 29** 
FVC (% pred) 107 ± 12 98 ± 22 94 ± 18 93 ± 26 
FEV1/FVC (%) 78 ± 5 70 ± 12 66 ± 11** 60 ± 14*** 
Reversibility (%) Nd 8 ± 12 11 ± 11 5 ± 8 
ACQ Nd 1.63 ± 1,31 2.16 ± 1,62 2.51 ± 1,3 
PC20M (mg/ml) >16 2.6 (0,2-14,2) 0.9 (0,1-22) 3.1 (0.11-16) 
Oral CS - 1 (9%) 3 (11%) 1 (7%) 
Inhaled CS - 8 (73%) 18  (67%) 12  (86%) 
LABA - 8 (73%) 17 (63%) 12  (86%) 
LTRA - 3 (27%) 13 (48%) 8  (57%) 
Theophylline - 0 (0%) 0 (0%) 4  (29%) 
Asthma Severity     
Mild - 2 (18%) 9 (33%) 2 (14%) 
Moderate - 6 (55%) 8 (30%) 4 (29%) 
Refractory - 3 (27%) 10 (37%) 8 (57%) 
 
Results are presented as absolute number, absolute number (percentage), mean ± SD or median 
(range). See table 1 for legends. ** p<0.01 and ***p< 0.001 versus healthy subjects.
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Table 6: Multivariate analysis on the relationship between and IL-29 (upper table) and IFN-β (lower 
table) ICS, sputum neutrophils and smoking status in asthmatics  
 
Univariate 
Model vs 
IL-29 (log) 
 Multivariate Model vs IL-29 (log) 
Factors β SE p R2  β SE p R2 
ICS dose (eq. 
beclomethasone) 
+0.0003 0.0002 0.152 0.037  +0.0001  0.0002 0.484 0.137
Sputum 
neutrophils (%) 
+0.0225  0.008 0.01 0.115  +0.019 0.009 0.038  
Smoking (ref. 
Never-Smoker) 
Ex-smoker 
Current-smoker 
 
+0.589 
+1.086 
 
0.531 
0.723 
0.282 0.046   
+0.296 
+0.422 
 
0.530 
0.787 
0.810 
 
 
 
Univariate 
Model vs 
IFN-β (log)
 Multivariate Model vs IFN-β (log) 
Factors β SE p R2  β SE p R2 
ICS dose (eq. 
beclomethasone) 
+0.0002 0.0002 0.346 0.016  -0.000005 0.0002 0.981 0.193 
Sputum 
neutrophils (%) 
+0.0276 0.008 0.002 0.167  +0.024 0.009 0.009  
Smoking (ref. 
Never-Smoker) 
Ex-smoker 
Current-smoker 
 
+0.896 
+1.340 
 
0.533 
0.725 
0.114 
 
0.077   
+0.578 
+0.797 
 
0.523 
0.776 
0.453 
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Table 7: Matrix of correlations between IFNs and ISGs  
  IL-29 IFN-β 
     
 p-value r p-value r 
Mx1 0,6884 0,05379 0,0342 0,2786 
OAS 0,0223 0,2997 < 0.0001 0,5261 
VIPERIN 0,0087 0,3414 < 0.0001 0,5309 
     
r: Spearman coefficients  were calculated for pooled asthmatics and healthy subjects. 
 
Table 8: Relationship between gene expression and percentage of sputum cell counts 
Sputum cell 
counts (%) 
IL-29 IFNβ Viperin OAS Mx1 
Macrophage 
r = - 0.39 
p = 0.0005 
r = - 0.37
p= 0.001 
r = - 0.3
p = 0.0092 
r = 0.11 
p = 0.3347 
r = 0.18 
p = 0.1196 
Lymphocyte 
r = - 0.26 
p = 0.0263 
r = - 0.21
p = 0.07 
r = - 0.08
p = 0.5193 
r = - 0.06 
p = 0.5989 
r = 0.05 
p = 0.6739 
Neutrophil 
r = 0.36 
p = 0.0015 
r = 0.39
p = 0.0006 
r = 0.4
p = 0.0004 
r = 0.07 
p = 0.5299 
r = 0.04 
p = 0.7118 
Eosinophil 
r = - 0.09 
p = 0.4634 
r = - 0.09
p = 0.4618 
r = - 0.15
p = 0.1871 
r = - 0.32 
p = 0.0053 
r = - 0.49 
p < 0.0001 
Epithelial cell 
r = - 0.21 
p = 0.0771 
r = - 0.25
p = 0.0339 
r = - 0.09
p = 0.4226 
r = - 0.05 
p = 0.6418 
r = - 0.03 
p = 0.7954 
Boldface reflects statistically significant correlation. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
Figure Legends 
Figure 1 
Expression of IL-29 and IFN-β on sputum cells in healthy subjects (open circles) and asthmatics 
(closed circles) (Upper panel). Expression of myxovirus resistance A (Mx1), oligoadenylate synthase 
(OAS) and viperin on sputum cells in healthy subjects (open circles) and asthmatic (closed circles). 
The bars represent the median. 
Figure 2 
Expression of IL-29, IFN-β, Viperin, Mx1 and OAS on sputum cells in asthmatics according to the 
inflammatory phenotype. Eos + means sputum sample with sputum eosinophils >3%, Neutro + 
means sputum sample with sputum neutrophil > 76%, Pauci means sputum sample with 
sputum  eosinophil and neutrophil < 3% and 76% respectively. The bars represent the median. 
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